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H
ereditary non-polyposis colorectal cancer (HNPCC), or
Lynch syndrome, is an autosomal dominant condition
predisposing to tumours of the large bowel and other
sites. In HNPCC, cancer predisposition is usually inherited as
a highly penetrant trait, with a tendency to the development
of multiple tumours. Clinical diagnosis of HNPCC is based on
the so-called modified ‘‘Amsterdam criteria’’,1 which include:
(a) the presence of at least three family members—one of
whom must be a first degree relative to two other members—
affected with carcinoma of the colon, rectum, endometrium,
small bowel, or urothelium; (b) a direct transmission of the
disease from parent to child; (c) the occurrence of at least one
tumour before the patient reaches 50 years of age; and (d) the
exclusion of a diagnosis of familial adenomatous polyposis.
The genetic defects underlying most HNPCC cases are
represented by constitutional point mutations of one of
several genes encoding for proteins of the DNA mismatch
repair complex. The vast majority of mutations are located in
the major mismatch repair genes MSH2 and MLH1
(International Collaborative Group on HNPCC Mutation
Database). The constitutional defects most commonly iden-
tified are nonsense, splice-site, or frameshift alterations,
which all predict the synthesis of shorter, non-functional
proteins. Tumours arising in carriers of mismatch repair gene
mutations are characterised by a high frequency of insertion
or deletion type somatic mutations within microsatellite
repeats.2 These are the expression of mismatch repair
deficiency, which arises when a second somatic mutation
affecting the wild-type allele fully inactivates the gene locus
already altered in the germline.3 Inactivation of a specific
mismatch repair locus in a HNPCC tumour is often revealed
by immunohistochemical methods, which show absence of
nuclear staining following incubation with antibodies against
the mismatch repair protein encoded by the mutant gene.4
In addition to genetic heterogeneity, HNPCC is also
characterised by a marked degree of allelic heterogeneity.
In fact, although some regions of MLH1/MSH2 appear to be
more frequently altered, mutations are spread all over the
whole gene sequences, and the mutational mechanisms are
heterogeneous5. Nevertheless, a few specific mutations are
observed at high frequencies in well-defined populations or
ethnic groups, because of founder effects. In Finland a major
share of HNPCC cases is accounted for by two MLH1
mutations.6 Founder HNPCC mutations have also been
identified in Denmark, Newfoundland, China, the United
States, and among Ashkenazi Jews.7–11 The presence of
common founder mutations can greatly facilitate the
molecular diagnosis of HNPCC by targeting mutational
analysis to specific gene regions as a first step.
We had previously identified an insertion affecting the last
codon of MLH1 in a large HNPCC family originating from
northern Italy (2269-2270insT).12 Analysis of further pedi-
grees allowed us to detect the same mutation in three
additional families from the same geographical area. We then
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Key points
N Hereditary non-polyposis colorectal cancer (HNPCC) is
genetically heterogeneous, with MSH2 and MLH1 the
most commonly involved genes. The mutational spec-
trum is highly heterogeneous, with alterations spread
over the whole coding sequences of the two genes.
Most mutations predict protein shortening by truncation
or internal deletion. A few mismatch repair gene
founder mutations have also been described.
N We analysed samples from HNPCC and suspected
HNPCC families from Modena and Reggio-Emilia. A
recurrent 1 bp insertion (2269-2270insT) within the
MLH1 gene was observed in 4/11 (36%) ‘‘Amsterdam’’
HNPCC families, but not in 19 ‘‘non-Amsterdam’’
familial colorectal cancer pedigrees or 65 unrelated
controls from the same region. Tumours developed by
mutation carriers did not show expression of the
MLH1 protein. To determine the functional conse-
quences of the DNA change, allele specific expres-
sion and protein expression were investigated. The
mutant and wild-type alleles displayed approximately
equal mRNA expression levels. Instability of the MLH1
mutant protein was documented using Western
blotting analysis. Haplotype analysis revealed that
the mutation could be traced to a common ancestor.
N We investigated the effects of a frameshift elongating
mutation occurring in the very last portion of the MLH1
gene. The pathogenicity of the mutation is largely
attributable to protein instability caused by synthesis of
a longer polypeptide. The finding of a founder effect is
relevant to the molecular diagnosis of HNPCC in this
region of Italy. The identification of founder mutations
with limited territorial distribution in other regions
should be facilitated by analysing HNPCC and
suspected HNPCC cases.
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performed molecular, immunohistochemical, and in vitro
expression studies to ascertain its origin and molecular
consequences.
SUBJECTS AND METHODS
Patients
Families enrolled in this study were found either through the
colorectal cancer registry of the district of Modena or by
interviews of patients attending a familial colorectal cancer
clinic. Familial colorectal cancers were subdivided into two
groups based on the modified Amsterdam criteria.1
‘‘Amsterdam’’ or HNPCC families met all of the Amsterdam
diagnostic criteria. ‘‘Non-Amsterdam’’ or ‘‘suspected’’
HNPCC pedigrees did not fulfil all diagnostic criteria, and
were characterised by a heterogeneous constellation of family
histories, with a minimum of two colorectal cancer occur-
rences in two first degree relatives diagnosed at any age. A
total of 11 Amsterdam and 19 non-Amsterdam families were
investigated. All families originated from the districts of
Modena and Reggio-Emilia, as ascertained by family names,
interviews with family members, and consultation of city
registries. A venous blood sample was drawn from each
individual who gave informed consent to participate in the
study aimed at screening for mismatch repair gene muta-
tions.
Control blood samples (n = 65) were obtained from
healthy blood donors without a history of colorectal cancer
in first degree relatives, following ascertainment of the origin
of their families from the Modena and Reggio-Emilia districts
and provision of informed consent.
Molecular analysis
Constitutional MLH1 and MSH2 mutations were searched on
peripheral leucocyte genomic DNA by a combination of
radioactive single-strand conformation polymorphism analy-
sis and direct sequencing, on a Perkin-Elmer Applied
Biosystem (Foster City, CA) 373 automated sequencer, and
reverse-transcription PCR, as previously described.13 A
restriction fragment length polymorphism PCR assay was
designed to detect the presence of the MLH1 2269-2270insT
mutation in relatives of proband carriers and in control
samples. The protocol involves amplifying exon 19 using the
forward intronic primer GACACCAGTGTATGTTGG and the
reverse primer GAGAAAGAAGAACACATCCC, located in the
39 untranslated region, followed by digestion of the PCR
product with the restriction enzyme DraI (20 000 U/ml; New
England BioLabs, Beverly, MA) at 37 C˚ and direct visualisa-
tion onto agarose gels stained with ethidium bromide. The
insertion introduces a novel DraI recognition site in the
amplified sequence. Therefore, the mutant allele is cut into
two fragments, whose sizes are 224 and 44 bp, respectively,
while the 268 bp wild-type product remains undigested on
incubation with DraI.
Total RNA extraction and cDNA preparation from lympho-
blastoid cell lines was performed as previously described.13
Amplification of a cDNA product spanning the 39 por-
tion of the MLH1 transcript was performed in the pre-
sence of primers annealing to exon 16 (forward:
AAGGCTGAGATGCTTGCAGACT) and to the 39 untranslated
region (reverse: GTTGGTACACTTTGTATATCACAC), respec-
tively. Cycling conditions were: initial denaturation at 94 C˚
for 5 min, followed by 30 cycles including 30 s at 94 C˚, 90 s at
60 C˚, and 60 s at 72 C˚, with a final extension lasting 5 min at
72 C˚. 5–10 ml of the reverse transcription PCR product were
digested with 0.3 ml of DraI. Samples were then loaded onto
agarose gels.
Microsatellite instability was assayed by testing at least five
microsatellite markers, always including the five reference
markers comprised in the microsatellite instability testing
panel advised by the Bethesda guidelines,14 on matched DNA
samples extracted from tumours embedded in paraffin and
normal colonic mucosa or fresh peripheral leucocytes, as
previously reported.15 Samples were considered to have high
levels of microsatellite instability when the instability was
observed at >25% markers.
Segregation of MLH1 linked polymorphic markers in
HNPCC pedigrees was investigated on peripheral blood
DNA. The polymorphisms tested included five microsatellite
loci (D3S1609, D3S1612, D3S1561, D3S1611, and D3S1298), and
two intragenic single base substitutions located within exon 8
and intron 145. The latter substitutions were typed by direct
sequencing. Analysis of microsatellite polymorphisms was
performed by PCR amplification in the presence of a32P-
dCTP, followed by electrophoresis on 6% denaturing poly-
acrylamide gels and autoradiographic detection. A total of 42
individuals, including 21 carriers of the 2269-2270insT
mutation, were analysed. Allele frequencies in the general
population were calculated by analysis of DNA samples of the
65 control blood donors.
Immunohistochemical analysis
Tissues were fixed in formalin, embedded in paraffin, and
sectioned at 6 mm. Following deparaffinisation and rehydra-
tion with xylene and ethanol, respectively, slides were
submitted to microwave antigen retrieval for pretreatment
(30 min, 350 W, in 10 mM citrate buffer, pH 6).
Immunoperoxidase staining using diaminobenzidine as a
chromogen was carried out with a Nexus automated staining
system (Ventena, Strasbourg Cedex, France). Mouse mono-
clonal antibodies against the MLH1 (G168-15; Pharmingen,
San Diego, CA) and MSH2 proteins (G129-1129;
Pharmingen, San Diego, CA) were used at a dilution of
1:40. Tumours were considered to show inactivation of MSH2
or MLH1 when complete absence of detectable nuclear
staining of neoplastic cells was observed. Definite nuclear
staining of adjacent non-neoplastic epithelium, stromal cells,
or lymphocytes served as an internal positive control.
In vitro expression of MLH1 2269-2270insT
The entire open reading frame of a 2484 bp MLH1 messenger
RNA was cloned into a pcDNA3.1 expression vector
(Invitrogen, Carlsbad, CA). The MLH1 2269-2270insT muta-
tion was generated by site directed mutagenesis using the
Quick-Change Site-directed mutagenesis kit (Promega,
Madison, WI). Human embryonic kidney fibroblast 293T
cells lacking expression of intrinsic MLH1 because of MLH1
promoter methylation were cotransfected with a pSG5
expression vector containing a full length PMS2 cDNA and
with pcDNA3.1 containing either wild-type or 2269-2270insT
MLH1. Extracts were prepared and 50 mg aliquots were
analysed by Western blotting as described.16
RESULTS
Mutational screening of the entire MLH1 and MSH2 genes
was performed in all HNPCC probands and in 19 suspected
HNPCC families. Two different mutations were identified in
pedigrees complying with the Amsterdam criteria. One of
these mutations was present in four apparently unrelated
families, two of which originated from the district of Modena
and two from the district of Reggio-Emilia. The recurrent
mutation was an insertion of a T between nucleotides 2269
and 2270 (c.2269-2270insT) of the MLH1 cDNA sequence,
within exon 19. This mutation is located in the last codon of
the gene, and is predicted to displace the termination codon
downstream. The new stop codon appears following 33 novel
coding triplets which, in the wild-type gene, are contained in
the 39 untranslated region. No other mutation was identified
in probands from the four families by direct sequencing of
2 of 6 Online mutation report
www.jmedgenet.com
MLH1 and MSH2. Relatives of the 2269-2270insT mutation
carriers were assayed by restriction fragment length poly-
morphism PCR. Seventeen additional carriers were identified
(data not shown) and the mutation was shown to
cosegregate with the disease phenotype in all families
(fig 1). To verify whether the 2269-2270insT could represent
a regional polymorphism, 65 control samples obtained by
regionally matched blood donors were investigated, and none
was found to carry the mutation.
To determine the effects of the mutation on mRNA, we
evaluated the expression of the wild-type and mutant alleles
by a restriction fragment length polymorphism PCR assay on
lymphoblastoid cDNA from two mutation carriers. Direct
visualisation of the reverse transcription PCR products on
gels stained with ethidium bromide showed that the two
alleles are expressed at approximately equal levels in
lymphoblastoid cells from both subjects (fig 2).
Microsatellite instability was evaluated in four colorectal
cancers and three endometrial carcinomas from seven 2269-
2270insT mutation carriers. All were found to have high
levels of microsatellite instability. MLH1 protein expression
was evaluated by immunohistochemistry in the same speci-
mens. All samples showed absence of the usual pattern of
nuclear staining observed in normal colonic mucosa follow-
ing incubation with anti-MLH1 antibodies (fig 3). Normal
MSH2 nuclear expression was present in all specimens.
Western blot analysis performed on 293T cells following
transfection of recombinant MLH1 showed the presence of a
larger band in cells containing the 2269-2270insT construct,
whose size was compatible with the predicted length of the
protein encoded by the mutant allele (fig 4). The intensity of
the band corresponding to the mutant product was con-
siderably lower than that of the wild-type MLH1 sequence
(fig 4), whilst expression of b-tubulin, used as an internal
Figure 1 Pedigrees of the families segregating the 2269-2270insT mutation. A detailed description of family AMD7 can be found in Ponz de Leon
et al.12 C, carrier of the MLH1 2269-2270insT mutation; NC, non-carrier. Haplotypes in the region surrounding MLH1 are shown on the left or at the
bottom of symbols corresponding to the individuals tested. Alleles are shown for the following markers, from top to bottom: D3S1561, D31612, exon 8
A/G at nucleotide 655, intron 14 G/A at position -19, and D3S1611. For each microsatellite locus, alleles are numbered by decreasing size, (at each
locus, number 1 indicates the allele with the highest repeat number).
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control, was comparable between the two cell lines (data not
shown). Expression of wild type recombinant PMS2 was also
found to be markedly reduced in the presence of 2269-
2270insT construct (fig 4).
Finally, to assess whether the mutant 2269-2270insT
alleles could be derived from a common founder, we
investigated the segregation of alleles at nearby polymorphic
markers in the four families (fig 5). A common haplotype
was observed in all mutation carriers analysed for this
purpose (fig 1). This haplotype spanned three intragenic as
well as three very close extragenic markers, and no
recombination was observed in this interval. On the other
hand, in two families, chromosomes carrying the mutant
allele showed recombination between MLH1 and the more
distal locus D3S1609.
DISCUSSION
The MLH1 mutation described in this study is peculiar from
both the molecular and the population genetics standpoints.
Its unusual molecular characteristic is the location in the last
codon of the gene and its predicted chain elongating effect. It
is generally assumed that mismatch repair gene mutations
contribute to neoplastic development through inactivation of
the system, which is rendered unable to repair DNA
mismatches, and possibly other functions. Therefore, most
proteins encoded by alleles associated with HNPCC lack
relevant domains due to either premature truncation or
internal deletion. Since the mutation investigated in this
study occurs at the very end of the MLH1 gene, it might well
represent a polymorphism restricted to a small geographical
region. However, pathogenicity of the 2269-2270insT muta-
tion is demonstrated by several lines of evidence. First, no
other significant MLH1 or MSH2 sequence change was
detected in the families segregating the 1 bp insertion. The
mutation segregated with the disease phenotype in all
families and was absent in control chromosomes from the
same region. It was associated with microsatellite instability
in all tumour samples investigated. Furthermore, absence of
staining following exposure to anti-MLH1 antibodies in
tumour samples confirms that the mismatch repair gene
implicated in cancer predisposition in these families is MLH1.
Figure 2 DraI digestion of MLH1 reverse transcription PCR products
extending from exon 16 to the 39 untranslated region. Analysis was
conducted on lymphoblastoid cell lines derived from two c.2269-
2270insT mutation carriers (lanes 1 and 2) and from two control
individuals (lanes C1 and C2). M, molecular size marker (100 bp
ladder). Arrows and numbers on the left indicate the sizes of the wild-
type product (514 bp), which is not digested by DraI, and of the larger
fragment (418 bp) obtained after digestion of the mutant allele (the
smaller 96 bp fragment was barely visible on the gel due to its very low
intensity).
Figure 3 Immunohistochemical analysis with anti-MLH1 antibodies of a
colorectal cancer from a carrier of the 2269-2270insT mutation. The
tumour (left) shows no staining, whereas a strong positive reaction is
visible in normal colonic mucosa (right).
Figure 4 Expression of recombinant MLH1 and PMS2 in 293T cells.
Extracts were prepared after cotransfection of human embryonic kidney
fibroblast 293T cells with the MLH1 and PMS2 vectors, and 50 mg
aliquots were analysed by Western blotting: wt, cotransfection with
vector containing wild-type MHL1; mut, co-transfection with vector
containing the MLH1 2269-2270insT mutation. Arrows and numbers on
the right side indicate the sizes of the expressed proteins.
Figure 5 Diagram of the MLH1 region on chromosome 3p, illustrating
the polymorphic markers investigated for haplotype analysis and their
approximate distances in cM17. The recombinant marker D3S1609 is
shadowed. Alleles at all other markers are conserved in the haplotype
carrying the 2269-2270insT mutation. Numbers in brackets indicate the
frequency of the mutation-associated alleles in the general population,
as determined by analysis of 65 healthy blood donors.
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Finally, a 4 bp duplication (TGTT) occurring at the same base
position, and therefore causing similar changes of the MLH1
protein, has been previously identified in two HNPCC
families.18 19 This duplication was shown to inhibit interac-
tion with PMS2 in a yeast two hybrid assay.20
In principle, the 2269-2270insT could affect mismatch
repair function through different mechanisms. Elongation of
the reading frame could interfere with mRNA processing and
stabilisation, leading to a significant reduction of mRNA
levels, as demonstrated for haemoglobin Constant Spring and
other mutant globins.21 Alternatively, the mutant gene could
produce normal amounts of mRNA, but protein elongation
might have a significant impact on its function or stability.
Since the results of expression studies performed in
lymphoblastoid cell lines from two MLH1 2269-2270insT
carriers indicate that mRNA derived from the mutant allele is
not significantly under expressed or unstable, it ensues that
some properties of the longer protein must be altered by the
mutation. Data obtained from in vitro expression studies
indicate that the mutation substantially reduces MLH1
protein stability. PMS2 stability was also secondarily affected,
since the PMS2 protein is rapidly degraded when it cannot
form functional heterodimers with MLH1. MLH1 and PMS2
expression in transfected 293T cells is the preliminary step
towards assessment of mismatch repair activity, which
requires substantial amounts of these proteins.16 However,
because of their instability, the levels of MLH1 and PMS2
were too low to proceed further with the functional
mismatch repair assay. Therefore, an effect of the mutation
on the function of residual MLH1 cannot be ruled out.
The 2269-2270insT mutation was identified in HNPCC
families originating from a small geographic area, comprising
the neighbouring districts of Modena and Reggio-Emilia in
Emilia-Romagna. The 2269-2270 insT has not been reported
so far in studies of HNPCC families from other areas of Italy5,
including 62 additional kindreds studied by us(22 and
unpublished data). These findings are indicative of a founder
effect, which is confirmed by the results of haplotype analysis
with MLH1 linked polymorphisms.
In conclusion, we have provided genetic and functional
evidence that the 2269-2270insT is an authentic pathogenetic
founder mutation, involved in HNPCC causation in a small
territory in northern Italy. The identification of founder
mutations with limited territorial distribution in other
European regions or in other parts of the world should be
facilitated by the analytical study of HNPCC and suspected
HNPCC cases selected from colorectal cancer registries, as
performed for part of the patient population investigated in
the present study.
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